Analysts Set Hikma Pharmaceuticals PLC (LON:HIK) Target Price at GBX 2,068.75

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six analysts that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is GBX 2,068.75 ($25.75).

Several research analysts have recently commented on the company. Berenberg Bank lifted their target price on Hikma Pharmaceuticals from GBX 1,960 ($24.40) to GBX 2,000 ($24.90) and gave the stock a "hold" rating in a research report on Monday, February 26th. Barclays reiterated an "equal weight" rating and issued a GBX 2,000 ($24.90) target price on shares of Hikma Pharmaceuticals in a research report on Monday, April 8th.

Hikma Pharmaceuticals Stock Down 0.7 %

LON HIK traded down GBX 12 ($0.15) during mid-day trading on Wednesday, reaching GBX 1,774 ($22.08). 270,399 shares of the company's stock traded hands, compared to its average volume of 425,837. Hikma Pharmaceuticals has a 1-year low of GBX 1,711 ($21.30) and a 1-year high of GBX 2,222 ($27.66). The company has a fifty day simple moving average of GBX 1,909.98 and a 200-day simple moving average of GBX 1,880.49. The company has a current ratio of 1.57, a quick ratio of 1.27 and a debt-to-equity ratio of 53.92. The company has a market cap of £3.94 billion, a price-to-earnings ratio of 2,659.06, a P/E/G ratio of 2.38 and a beta of 0.45.

Hikma Pharmaceuticals Increases Dividend

The company also recently disclosed a dividend, which will be paid on Friday, May 3rd. Stockholders of record on Thursday, March 21st will be paid a $0.47 dividend. This represents a dividend yield of 1.86%. The ex-dividend date of this dividend is Thursday, March 21st. This is an increase from Hikma Pharmaceuticals's previous dividend of $0.25. Hikma Pharmaceuticals's payout ratio is currently 8,507.46%.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.